Data from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

<div>AbstractPurpose:<p>Alterations in the <i>KEAP1</i>/<i>NFE2L2</i> (NRF2)/<i>CUL3</i> pathway occur in ∼20% of human head and neck squamous cell carcinomas (HNSCC) and are associated with resistance to standard-of-care therapy. However, this pathway’s role in radiotherapy resistance in HNSCC has not been well studied.</p>Experimental Design:<p>We generated genetically engineered mouse models and developed primary murine cancer cell lines harboring mutations commonly observed in human HNSCC, including inducible activation of <i>PIK3CA</i> and deletion of <i>Trp53</i>, with or without <i>Keap1</i> loss. Primary tumors were initiated via 4-hydroxytamoxifen injection ± the tobacco carcinogen benzo[a]pyrene (BAP) into the oral buccal mucosa. Tumors were analyzed by Western blotting, IHC, and RNA sequencing and subjected to fractionated radiotherapy to investigate the role of the KEAP1/NRF2 pathway in radioresistance and modulation of the tumor-immune microenvironment.</p>Results:<p>BAP exposure accelerated primary tumor formation within 1 month, with histologic analysis confirming invasive squamous cell carcinoma, validated by cytokeratin and differentiation marker expression. Primary cell lines derived from <i>Keap1</i>-haploinsufficient tumors exhibited upregulation of NRF2 target genes and a radioresistant phenotype, which was reversed after Nrf2 knockdown <i>in vitro</i>. Bulk RNA sequencing revealed that <i>Keap1</i> haploinsufficiency correlated with NRF2 pathway activation, increased myeloid infiltration, and enhanced angiogenic signatures. <i>In vivo</i>, <i>Keap1</i> haploinsufficiency promoted accelerated tumor growth and decreased survival. Finally, using fractionated radiotherapy, we showed that <i>Keap1</i>-haploinsufficient primary tumors were significantly more radioresistant than <i>Keap1</i>-proficient tumors, regardless of BAP exposure.</p>Conclusions:<p>These data demonstrate that <i>Keap1</i> haploinsufficiency in HNSCC is linked to unfavorable tumor-immune microenvironment, aggressive growth, and a radioresistant phenotype.</p></div>

Authors

Publication Details

Published
2025-10-01
DOI
https://doi.org/10.1158/1078-0432.c.8065082
Primary Topic
Genomics, phytochemicals, and oxidative stress
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Data from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

William Henry Hudson, Patricia Castro, Vlad C. Sandulache, William K. Decker et al.
Genomics, phytochemicals, and oxidative stress
article

Data from Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma

William Henry Hudson, Patricia Castro, Vlad C. Sandulache, William K. Decker, Rutulkumar Patel, Yan Ma, Jeffrey I. Everitt, Rashid Abdullah Osman, Maciej J. Żelazowski, Yvonne Marie Mowery, Nerissa T. Williams, Jeffrey N. Myers, David G. Kirsch, Lixia Luo, Mitchell J. Frederick, Kalil Saab
article en

Abstract

<div>AbstractPurpose:<p>Alterations in the <i>KEAP1</i>/<i>NFE2L2</i> (NRF2)/<i>CUL3</i> pathway occur in ∼20% of human head and neck squamous cell carcinomas (HNSCC) and are associated with resistance to standard-of-care therapy. However, this pathway’s role in radiotherapy resistance in HNSCC has not been well studied.</p>Experimental Design:<p>We generated genetically engineered mouse models and developed primary murine cancer cell lines harboring mutations commonly observed in human HNSCC, including inducible activation of <i>PIK3CA</i> and deletion of <i>Trp53</i>, with or without <i>Keap1</i> loss. Primary tumors were initiated via 4-hydroxytamoxifen injection ± the tobacco carcinogen benzo[a]pyrene (BAP) into the oral buccal mucosa. Tumors were analyzed by Western blotting, IHC, and RNA sequencing and subjected to fractionated radiotherapy to investigate the role of the KEAP1/NRF2 pathway in radioresistance and modulation of the tumor-immune microenvironment.</p>Results:<p>BAP exposure accelerated primary tumor formation within 1 month, with histologic analysis confirming invasive squamous cell carcinoma, validated by cytokeratin and differentiation marker expression. Primary cell lines derived from <i>Keap1</i>-haploinsufficient tumors exhibited upregulation of NRF2 target genes and a radioresistant phenotype, which was reversed after Nrf2 knockdown <i>in vitro</i>. Bulk RNA sequencing revealed that <i>Keap1</i> haploinsufficiency correlated with NRF2 pathway activation, increased myeloid infiltration, and enhanced angiogenic signatures. <i>In vivo</i>, <i>Keap1</i> haploinsufficiency promoted accelerated tumor growth and decreased survival. Finally, using fractionated radiotherapy, we showed that <i>Keap1</i>-haploinsufficient primary tumors were significantly more radioresistant than <i>Keap1</i>-proficient tumors, regardless of BAP exposure.</p>Conclusions:<p>These data demonstrate that <i>Keap1</i> haploinsufficiency in HNSCC is linked to unfavorable tumor-immune microenvironment, aggressive growth, and a radioresistant phenotype.</p></div>

Openalex Percentile: Top 76%
Genomics, phytochemicals, and oxidative stress
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.